Immatics N.V
IMTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.31B
Close$
$-2.85
128.8% downside
Current Fair Value
128.8% downsideOvervalued by 128.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.31 Billion |
|---|---|
| Enterprise Value | $1.04 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.54 |
| Beta | 1.3 |
| Outstanding Shares | 134,644,947 |
Return
| Return on Equity | -45.50% |
|---|---|
| Return on Assets | -38.17% |
| Return on Invested Capital | -47.46% |
Valuation & Multiples
| P/E Ratio | -5.35 |
|---|---|
| PEG | -11.28 |
| Price to Sales | - |
| Price to Book Ratio | 3.3 |
| Enterprise Value to Revenue | 27.88 |
| Enterprise Value to EBIT | -4.48 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$9.79 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$11.77 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 2.00% |
|---|---|
| Total Calls | 22,600▼ 98.68% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 85.83%▲ 2.20% |
|---|---|
| Total Invested | $1.06B▼ 0.28% |
| Investors Holding | 85▲ 5.00% |
ESG Score
No data
About Immatics N.V
2,020 employeesImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is th...